Literature DB >> 2571410

Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up.

J V Selby1, G D Friedman, B H Fireman.   

Abstract

Using computerized pharmacy records from 1969 to 1973 for a cohort of 143,574 members of the Kaiser Permanente Medical Care Program, we have been testing associations of 215 drugs or drug groups with subsequent incidence of cancer at 56 sites. This paper presents findings with follow-up through 1984. There were 227 statistically significant (P less than 0.05, two-tailed) associations: 170 positive, 57 negative. Some were undoubtedly chance findings; others were likely due to confounding by unmeasured covariables. However, several associations suggested hypotheses for further studies and/or the need for continued observation. Most notable among findings not previously reported were associations of several antibiotics, both oral and topical, with lung cancer. These associations could not be explained by indications for drug use or by differences in smoking habits between users and nonusers, and suggest a possible link between the occurrence of bacterial infections and risk for cancer. In general, our results continue to suggest that most medications used during that period did not affect cancer incidence substantially. However, for less frequently prescribed medications, our power to detect moderate increases in cancer risk was quite low.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571410

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

Authors:  Elizabeth A Platz; Srinivasan Yegnasubramanian; Jun O Liu; Curtis R Chong; Joong Sup Shim; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci; William G Nelson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

2.  Antihistamine use and immunoglobulin E levels in glioma risk and prognosis.

Authors:  E Susan Amirian; Deborah Marquez-Do; Melissa L Bondy; Michael E Scheurer
Journal:  Cancer Epidemiol       Date:  2013-08-30       Impact factor: 2.984

Review 3.  Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate.

Authors:  H Stopper; S Walitza; A Warnke; M Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

4.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

Review 5.  Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Authors:  Gary D Friedman; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

6.  Medication use and multiple myeloma risk in Los Angeles County.

Authors:  Daniel S Nuyujukian; Jenna Voutsinas; Leslie Bernstein; Sophia S Wang
Journal:  Cancer Causes Control       Date:  2014-07-01       Impact factor: 2.506

Review 7.  Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations.

Authors:  Mark L Wolraich; Laura McGuinn; Melissa Doffing
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 8.  Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

Authors:  Johnny Graham; David Coghill
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Obesity and multiple myeloma.

Authors:  G D Friedman; L J Herrinton
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

10.  The effects of tricyclic antidepressants on breast cancer risk.

Authors:  C R Sharpe; J-P Collet; E Belzile; J A Hanley; J-F Boivin
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.